[-] Show simple item record

dc.contributor.advisorReinero, Carol R.eng
dc.contributor.authorEberhardt, Jason M.eng
dc.date.issued2010eng
dc.date.submitted2010 Springeng
dc.descriptionThe entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file.eng
dc.descriptionTitle from PDF of title page (University of Missouri--Columbia, viewed on July 13, 2010).eng
dc.descriptionVita.eng
dc.descriptionThesis advisor: Carol R. Reineroeng
dc.description"May 2010"eng
dc.descriptionM.S. University of Missouri-Columbia 2010.eng
dc.description.abstractExperimental asthma was induced in 10 cats using Bermuda grass allergen (BGA) and cats were randomly selected to receive either feG (1 mg/kg, PO) or saline for 2 weeks, followed by a 2 week washout period before receiving the alternate treatment. A clinical scoring system was employed and bronchoalveolar lavage fluid (BALF) and blood were collected prior to and after each 2 week treatment. Cytology and cytokine analysis were performed on BALF samples and in vitro cytokine restimulation was performed on peripheral blood mononuclear cells (PBMCs). There was no significant difference between the treatment groups in BALF total nucleated cell counts or eosinophil percentages. Greater than 40% of the BALF supernatant samples had IL-1, IL-4, IL-6, CXCL-8 and IFN-[gamma] concentrations below the lower limit of detection of the assay regardless of time point or treatment administered. Interleukin-4 and IFN-[gamma] concentrations in the cell culture supernatant from stimulated PBMCs were below the lower limit of detection for all samples. There was no significant difference in BALF or plasma TNF activity or clinical scores between treatment groups. In cats with experimental asthma, daily use of feG during chronic aeroallergen exposure did not dampen eosinophilic airway inflammation, alter cytokine profiles in the plasma or BALF, or decrease clinical signs associated with allergen challenge. These results support that feG at this dosage can not be recommended as monotherapy for the chronic treatment of allergic asthma in cats.eng
dc.description.bibrefIncludes bibliographical referenceseng
dc.format.extentix, 38 pageseng
dc.identifier.merlinb77175050eng
dc.identifier.oclc647800755eng
dc.identifier.urihttp://hdl.handle.net/10355/8084
dc.identifier.urihttps://doi.org/10.32469/10355/8084eng
dc.languageEnglisheng
dc.publisherUniversity of Missouri--Columbiaeng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. Graduate School. Theses and Dissertations. Theses. 2010 Theseseng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
dc.sourceSubmitted by University of Missouri--Columbia Graduate School.eng
dc.subject.lcshCats -- Diseases -- Treatmenteng
dc.subject.lcshAsthma -- Treatmenteng
dc.subject.lcshOligopeptides -- Immunologyeng
dc.titleImmunomodulators in feline asthmaeng
dc.typeThesiseng
thesis.degree.disciplineVeterinary biomedical sciences (MU)eng
thesis.degree.grantorUniversity of Missouri--Columbiaeng
thesis.degree.levelMasterseng
thesis.degree.nameM.S.eng


Files in this item

[PDF]
[PDF]
[PDF]

This item appears in the following Collection(s)

[-] Show simple item record